Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib

Hehlgans, Stephanie; Booms, Patrick; Güllülü, Ömer; Sader, Robert; Rödel, Claus; Balermpas, Panagiotis; Rödel, Franz; Ghanaati, Shahram

doi:10.3390/ijms19092485

Citations

Citation copied

Hehlgans, S., Booms, P., Güllülü, Ö., Sader, R., Rödel, C., Balermpas, P., Rödel, F., & Ghanaati, S. (2018). Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. International Journal of Molecular Sciences, 19(9), 2485. https://doi.org/10.3390/ijms19092485

Abstract

Vismodegib, an inhibitor of the Hedgehog signaling pathway, is an approved drug for monotherapy in locally advanced or metastatic basal cell carcinoma (BCC). Data on combined modality treatment by vismodegib and radiation therapy, however, are rare. In the present study, we examined the radiation sensitizing effects of vismodegib by analyzing viability, cell cycle distribution, cell death, DNA damage repair and clonogenic survival in three-dimensional cultures of a BCC and a head and neck squamous cell carcinoma (HNSCC) cell line. We